Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs - Netherlands
doi 10.1007/s10637-017-0479-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors

Oncologist
Cancer ResearchMedicineOncology
2017English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Phase I Dose‐escalation Study of Volasertib in Pediatric Patients With Acute Leukemia or Advanced Solid Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy